Effects of enalapril,candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker

Abstract

Background: The long-term effects of the angiotensin-receptor blocker candesartan, the angiotensin-converting enzyme inhibitor enalapril or their combination have been incompletely studied in a large cohort of patients with heart failure not treated with beta-blockers. The objective of this study was to investigate the changes in neurohormones and LV volumes and ejection fraction in patients treated with enalapril, candesartan, or enalapril plus candesartan without concomitant beta-blocker therapy.

Methods: Three hundred and ninety-two patients from the RESOLVD pilot study not treated with a beta-blocker at baseline or at any time during the trial were analyzed. Norepinephrine, endothelin-1, big endothelin-1, angiotensin-II, aldosterone, N-terminal proANP, BNP, and radionuclide angiography were measured before and after 43 weeks of treatment with candesartan alone (n = 162), or enalapril alone (n = 45), or candesartan plus enalapril (n = 185). Endpoints were assessed at baseline and after 43 weeks of therapy.

Results: LV end-diastolic and end-systolic volumes increased significantly at 43 weeks in all groups except for patients treated with enalapril plus candesartan. BNP decreased at 43 weeks only in patients receiving dual angiotensin-II suppression (-6.1 ± 37.8 pmol/l). Angiotensin-II levels were significantly increased in patients treated with candesartan (+23.6 ± 47.1 pg/ml; p<0.05).

Conclusion: We conclude that angiotensin-II modulation, with enalapril and candesartan, without concomitant utilization of beta-blocker lead to a decrease in BNP and an attenuation of the increase in LV end-diastolic and end-systolic volumes without a reversal of this process in the long term.

Keywords

congestive heart failure angiotensin-converting enzyme inhibitors neurohormones LV remodelling angiotensin receptor blockers natriuretic peptides

References

Andersson, O.K. and Neldam, S. (1998) The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan, Blood Press 7: 53-59.

Aupetit-Faisant, B. , Battaglia, C. , Zenatti, M. , Emeric-Blanchouin, N. and Legrand, J.C. (1993) Hypoaldosteronism accompanied by normal or elevated mineralocorticosteroid pathway steroid: A marker of adrenal carcinoma, J Clin Endocrinol Metab 76: 38-43.

Blumenfeld, J.D. , Sealy, J.E. , Mann, S.J. , Bragat, A. , Marion, R. , Pecker, M.S. et al. (1999) Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects, Am J Hypertens 12: 451-459.

Butler, J. , Khadim, G. , Belue, R. , Chomsky, D. , Dittus, R.S. , Griffin, M. et al. (2003) Tolerability to βblocker therapy among heart failure patients in clinical practice, J Cardiac Fail 9: 203-209.

Campbell, D.J. , Aggarwal, A. , Esler, M. and Kaye, D. (2001) β-blockers, angiotensin II, and ACE inhibitors in patients with heart failure, Lancet 358: 1609-1610.

Cavasin, M.A. , Yang, X.P. , Liu, Y.H. , Mehta, D. , Karumanchi, R. , Bulagannawar, M. et al. (2000) Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure, J Cardiovasc Pharmacol 36: 472-480.

Cernacek, P. and Stewart, D.J. (1989) Immunoreactive endothelin in human plasma: Marked elevations in patients in cardiogenic shock, Biochem Biophys Res Commun 161: 562-567.

Cohn, J.N. , Tognoni, G. , Valsartan Heart Failure Trial Investigators (2001) A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure, N Engl J Med 345:1667-1675.

Dickstein, K. , Chang, P. , Willenheimer, R. , Haunsø, S. , Remes, J. , Hall, C. et al. (1995) Comparison of the effects of losartan and enalapril on clinical status and exercise performance in patients with moderate or severe chronic heart failure, J Am Coll Cardiol 26: 438-445.

10.

Dupuis, J. , Rouleau, J.L. and Cernacek, P. (1998) Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction, Circulation 98: 1684-1687.

11.

Guazzi, M. , Palermo, P. , Pontone, G. , Susini, F. and Agostoni, P. (1999) Synergistic efficacy of enalapril and losartan on exercise performance and oxygen consumption at peak exercise in congestive heart failure, Am J Cardiol 84: 1038-1043.

12.

Kaufman, H. , Oribe, E. and Olivier, J.E. (1991) Plasma endothelin during upright tilt: Relevance for orthostatic hypertension?, Lancet 338: 1542-1545.

13.

Lang, R.M. , Elkayam, U. , Yellen, L.G. , Krauss, D. , McKelvie, R.S. , Vaughan, D.E. et al. (1997) Comparative effects of losartan and enalapril on exercise capacity and clinical status in patients with heart failure. The Losartan Pilot Exercise Study Investigators, J Am Coll Cardiol 30: 983-991.

14.

Latini, R. , Masson, S. , Anand, I. , Judd, D. , Maggioni, A.P. , Chiang, Y.T. et al. for the Valsartan Heart Failure Trial Investigators. (2002) Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT), Circulation 106: 2454-2458.

15.

Liu, Y.H. , Yang, X.P. , Sharov, V.G. , Nass, O. , Sabbah, H.N. , Peterson, E. et al. (1997) Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors, J Clin Invest 99: 1926-1935.

16.

Maggioni, A.P. , Anand, I. , Gottlieb, S.O. , Latini, R. , Tognoni, G. , Cohn, J.N. et al. (2002) Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors, J Am Coll Cardiol 40: 1414-1421.

17.

Masson, S. , Latini, R. , Anand, I.S. , Barlera, S. , Judd, D. , Salio, M. et al. for the Val-HeFT Investigators ( 2006) The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure trial (Val-HeFT), J Card Fail 12: 375-380.

18.

McKelvie, R.S. , Yusuf, S. , Pericak, D. , Avezum, A. , Burns, R.J. and Probstfield, J. (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study, Circulation 100: 1056-1064.

19.

McMurray, J.J. , Ostergren, J. , Swedberg, K. , Granger, C.B. , Held, P. , Michelson, E.L. et al. for the CHARM Investigators and Committees. (2003) Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting enzyme inhibitors: The CHARM-Added trial. Lancet 362: 767-771.

20.

Moller, J.E. , Dahlstrom, U. , Gotzsche, O. , Lahiri, A. , Skagen, K. , Andersen, G.S. et al. for the OPTIMAAL Study Group (2004) Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: Results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiography substudy, Am Heart J 147: 494-501.

21.

Omland, T. , Lie, R.T. , Aakvaag, A. , Aarsland, T. and Dickstein, K. (1994) Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction, Circulation 89: 1573-1579.

22.

Onodera, H. , Matsunaga, T. , Tamura, Y. , Maeda, N. , Higuma, T. , Sasaki, S. et al. (2005) Enalapril suppresses ventricular remodeling more effectively than losartan in patients with acute myocardial infarction , Am Heart J 150: 689.

23.

Pitt, B. , Poole-Wilson, P.A. , Segal, R. , Martinez, F.A. , Dickstein, K. , Camm, A.J. et al. on behalf of the ELITE II Investigators. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587.

24.

Resolvd Investigators (2000) Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy. The randomized evaluation of strategies for left ventricular dysfunction pilot study, Circulation 101: 378-384.

25.

Schuller, M. , Stetter, R. , Skrabal, S. , Missbichler, A. , Woloszczuk, W. and Hartter, E. (1991) Radioimmunoassay of immunoreactive C-terminal big-endothelin , Eur J Clin Chem Clin Biochem 29: 147-150.

26.

Tsuyuki, R.T. , Yusuf, S. , Rouleau, J.L. , Maggioni, A.P. , McKelvie, R.S. , Wiecek, E.M. et al. (1997) Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study, Can J Cardiol 13: 1166-1174.

27.

Van Beneden, R. , Gurne, O. , Selvais, P.L. Ahn, S.A. , Robert, A.R. , Ketelslegers, J.M. et al. (2004) Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: A 7-year follow-up study, J Card Fail 10: 490-495.

28.

Vanderheyden, P.M. , Fierens, F.L. , De Backer, J.P. , Fraeyman, N. and Vauquelin, G. (1999) Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors, Br J Pharmacol 126: 1057-1065.

29.

Vauquelin, G. , Fierens, F. and Van Liefde, I. (2006) Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans , J Hypertens 24: S23-S30.

30.

Watz, R. , Ekstrand, A.B. , Engelbrektson, V. and Beermann, B. (2005) Treatment with angiotensin converting enzyme inhibitors, angiotensin-IIantagonists and beta-blockers in an unselected group of patients with chronic heart failure, Eur J Clin Pharmacol 61: 209-214.

31.

White, M. , Lepage, S. , Lavoie, J. , De Denus, S. , Leblanc, M.H. and Gossard, D. (2007) Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure, J Card Fail 13: 86-94.

32.

White, M. , Rouleau, J.L. , Hall, C. Arnold, M. , Harel, F. and Sirois, P. (2001) Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction , Am Heart J 142: 1056-1064.

33.

Wong, M. , Staszewsky, L. , Latini, R. , Barlera, S. , Volpi, A. , Chiang, Y.T. et al. for the Val-HeFT Heart Failure Trial Investigators (2002) Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study , J Am Coll Cardiol 40: 970-975.

34.

Yoshiyama, M. , Omura, T. , Takeuchi, K. , Kim, S. , Shimada, K. , Yamagishi, H. et al. (2001) Angiotensin blockage inhibits increased JNKs, AP-1 and NF-kappa B DNA-binding activities in myocardial infarcted rats , J Mol Cell Cardiol 33: 799-810.